Literature DB >> 14502664

Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations.

Hani T S Benamer1, Wolfgang H Oertel, Jim Patterson, Donald M Hadley, Oliver Pogarell, H Höffken, A Gerstner, Donald G Grosset.   

Abstract

To record prospectively, from early presentation, the clinical features of parkinsonism and tremor disorders, in relation to evidence of dopaminergic deficit shown with [(123)I]-FP-CIT (DaTSCAN, Amersham Health) single photon emission computerised tomography (SPECT). Clinical signs were recorded in 62 patients, of whom 24 failed standard Parkinson's disease (PD) and essential tremor criteria, and 38 fulfilled UK Brain Bank step 1 PD criteria. Striatal radioligand uptake was graded visually as normal or abnormal, and specific:nonspecific ratios were calculated. Bradykinesia and rigidity showed significant overall association with abnormal scans (P < or = 0.003), but rest tremor did not (P = NS). In the 24 patients not fulfilling specific criteria (mean age 63 [SD 9] years, disease duration 3 [SD 4] years), 10 (42%) had abnormal visual SPECT assessment and 14 (58%) had normal scans. Of 38 patients with early PD by clinical criteria (mean age 60 [SD 9] years, disease duration 3 [SD 1.7] years), 33 (87%) were visually abnormal. Baseline clinical diagnosis corresponded with SPECT imaging results in 51 of 62 cases (82%), which increased to 56 of 62 cases (90%) with amendment of seven clinical diagnoses at 3 months (blind to SPECT results). Akinetic-rigid cardinal diagnostic features of parkinsonism associate well with dopaminergic deficit in patients with early and mild clinical features. When these clinical features are uncertain, or the patient fails clinical diagnostic criteria, testing for dopaminergic deficit with [(123)I]-FP-CIT SPECT may assist the diagnostic process. Copyright 2003 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14502664     DOI: 10.1002/mds.10482

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  28 in total

1.  Rivastigmine for dementia associated with Parkinson's disease.

Authors:  John Morgan; Kapil D Sethi
Journal:  Curr Neurol Neurosci Rep       Date:  2005-07       Impact factor: 5.081

2.  Growth hormone response in low-dose apomorphine test correlates with nigrostriatal dopamine transporter binding in patients with Parkinson's disease.

Authors:  S Happe; T Tings; W Koch; J Welsch; K Helmschmied; P C Baier; J Meller; W Wuttke; W Paulus; K Tatsch; C Trenkwalder
Journal:  J Neural Transm (Vienna)       Date:  2006-12-28       Impact factor: 3.575

3.  The impact of DaTscan on the diagnosis and management of movement disorders: A retrospective study.

Authors:  Kimberly D Seifert; Jonathan I Wiener
Journal:  Am J Neurodegener Dis       Date:  2013-03-08

4.  Neuroanatomical correlates of the inhibition of tremulous jaw movements in rats by a combination of memantine and Δ9 -tetrahydrocannabinol.

Authors:  Ilya D Ionov; Irina I Pushinskaya; David D Frenkel; Niсholas P Gorev; Larissa A Shpilevaya
Journal:  Br J Pharmacol       Date:  2020-01-24       Impact factor: 8.739

Review 5.  Motor automaticity in Parkinson's disease.

Authors:  Tao Wu; Mark Hallett; Piu Chan
Journal:  Neurobiol Dis       Date:  2015-06-21       Impact factor: 5.996

Review 6.  Functional neuroimaging in Parkinson's disease.

Authors:  Martin Niethammer; Andrew Feigin; David Eidelberg
Journal:  Cold Spring Harb Perspect Med       Date:  2012-05       Impact factor: 6.915

7.  Parkinson's disease tremor-related metabolic network: characterization, progression, and treatment effects.

Authors:  Hideo Mure; Shigeki Hirano; Chris C Tang; Ioannis U Isaias; Angelo Antonini; Yilong Ma; Vijay Dhawan; David Eidelberg
Journal:  Neuroimage       Date:  2010-09-17       Impact factor: 6.556

8.  Functional connectivity of cortical motor areas in the resting state in Parkinson's disease.

Authors:  Tao Wu; Xiangyu Long; Liang Wang; Mark Hallett; Yufeng Zang; Kuncheng Li; Piu Chan
Journal:  Hum Brain Mapp       Date:  2010-08-25       Impact factor: 5.038

Review 9.  Non-dopaminergic treatments for motor control in Parkinson's disease.

Authors:  Susan H Fox
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

10.  Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome.

Authors:  S Hesse; C Oehlwein; H Barthel; J Schwarz; D Polster; A Wagner; O Sabri
Journal:  J Neural Transm (Vienna)       Date:  2006-02-06       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.